阿替唑单抗
贝伐单抗
肝细胞癌
医学
内科学
肿瘤科
斯科普斯
胃肠病学
梅德林
癌症
彭布罗利珠单抗
化疗
免疫疗法
政治学
法学
作者
Magdalena Espinoza,Maishara Muquith,Mir Lim,Hao Zhu,Amit G. Singal,David Hsiehchen
标识
DOI:10.1053/j.gastro.2023.02.042
摘要
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of hepatocellular carcinoma (HCC) by inducing meaningful rates of antitumor responses and having favorable toxicity profiles. Based on large, randomized phase III trials, including the IMbrave150 study testing atezolizumab plus bevacizumab vs sorafenib, combination ICI regimens have emerged as the preferred frontline treatments for HCC based on their overall survival (OS) benefit.1,2 HCC biology may be influenced by distinct etiologies underlying tumorigenesis including viral infections, alcohol-related injury, and metabolic causes.
科研通智能强力驱动
Strongly Powered by AbleSci AI